Scientists hunt for genetic signs that show which breast cancer patients will benefit from kisqali
NCT ID NCT05529862
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study collects tumor and blood samples from 241 women with HR+/HER2- advanced breast cancer before and after treatment with ribociclib (Kisqali) plus hormone therapy. Researchers will analyze DNA and RNA changes to find markers that predict who responds well and who develops resistance. The goal is to better understand why some patients benefit while others relapse, and to identify new drug targets for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib (Kisqali) plus endocrine therapy
What this could lead to
If successful, this could help doctors predict which patients will benefit from ribociclib and endocrine therapy, and identify new treatment targets for those who don't respond.
What could go wrong
This is an observational, biomarker-focused study, not a treatment trial. It may not lead to immediate changes in patient care, and the findings might not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC BREAST CANCER (BC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Palbociclib Breast Cancer Study in Gulf Region (NCT04916509)
- Lerociclib for Advanced Breast Cancer Trial (NCT05085002)
- Liquid Biopsy Test for Breast Cancer Mutations NCT06762483
- COMBINE Trial: Elacestrant & Exemestane for Brea NCT07395336
- Palbociclib + AI vs AI Alone in HR+/HER2- MBC (NCT06086340)
- PF-06873600 Cancer Trial for HR+ Breast Cancer (NCT03519178)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Paoli Calmettes
Marseille, France